Show simple item record

dc.contributor.authorKatikireddi, Srinivasa Vittal
dc.contributor.authorCerqueira-Silva, Thiago
dc.contributor.authorVasileiou, Eleftheria
dc.contributor.authorRobertson, Chris
dc.contributor.authorAmele, Sarah
dc.contributor.authorPan, Jiafeng
dc.contributor.authorTaylor, Bob
dc.contributor.authorBoaventura, Viviane
dc.contributor.authorWerneck, Guilherme Loureiro
dc.contributor.authorFlores-Ortiz, Renzo
dc.contributor.authorAgrawal, Utkarsh
dc.contributor.authorDocherty, Annemarie B.
dc.contributor.authorMcCowan, Colin
dc.contributor.authorMcMenamin, Jim
dc.contributor.authorMoore, Emily
dc.contributor.authorRitchie, Lewis D.
dc.contributor.authorRudan, Igor
dc.contributor.authorShah, Syed Ahmar
dc.contributor.authorShi, Ting
dc.contributor.authorSimpson, Colin R.
dc.contributor.authorBarreto, Mauricio L.
dc.contributor.authorOliveira, Vinicius de Araujo
dc.contributor.authorBarral-Netto, Manoel
dc.contributor.authorSheikh, Aziz
dc.date.accessioned2022-01-07T11:31:01Z
dc.date.available2022-01-07T11:31:01Z
dc.date.issued2022-01-01
dc.identifier.citationKatikireddi , S V , Cerqueira-Silva , T , Vasileiou , E , Robertson , C , Amele , S , Pan , J , Taylor , B , Boaventura , V , Werneck , G L , Flores-Ortiz , R , Agrawal , U , Docherty , A B , McCowan , C , McMenamin , J , Moore , E , Ritchie , L D , Rudan , I , Shah , S A , Shi , T , Simpson , C R , Barreto , M L , Oliveira , V D A , Barral-Netto , M & Sheikh , A 2022 , ' Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time : a retrospective, population-based cohort study in Scotland and Brazil ' , The Lancet , vol. 399 , no. 10319 , pp. 25-35 . https://doi.org/10.1016/S0140-6736(21)02754-9en
dc.identifier.issn0140-6736
dc.identifier.otherPURE: 211307380
dc.identifier.otherPURE UUID: 4e6d66b4-bd2f-464b-b4ea-7539970ea9e7
dc.identifier.otherScopus: 85121923761
dc.identifier.urihttps://hdl.handle.net/2164/17802
dc.descriptionFunding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). Additional support has been provided through Public Health Scotland and Scottish Government Director General Health and Social Care. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK government. The Brazilian component is part of the Fiocruz VigiVac project on continuous digital evaluation of the national anti-COVID-19 immunisation programme. SVK and SA acknowledge funding from an NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the MRC (MC_UU_00022/2), and the Scottish Government Chief Scientist Office (SPHSU17). This partnership between Brazil and Scotland was established through funding from the NIHR (GHRG /16/137/99) using UK aid from the UK Government to support global health research. This study was partially supported by a donation from the Fazer o Bem Faz Bem programme. The authors thank DATASUS for its excellent work in providing unidentified databases. GLW, MLB, and MB-N are research fellows from the Brazilian National Research Council. GLW acknowledges funding from FAPERJ (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; E-26/210.180/2020). We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available; Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK); and Pam McVeigh, Amanda Burridge, and Afshin Dastafshan (Public Health Scotland, Glasgow, UK) for their support with project management and administration. Funding Information: SVK is a member of the UK Government's Scientific Advisory Group on Emergencies subgroup on ethnicity, the Cabinet Office's International Best Practice Advisory Group, and was co-chair of the Scottish Government's Expert Reference Group on Ethnicity and COVID-19. CR reports grants from the Medical Research Council (MRC) and Public Health Scotland, during the conduct of the study, and is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group, Scientific Pandemic Influenza Group on Modelling, and Medicines and Healthcare products Regulatory Agency Vaccine Benefit and Risk Working Group. AS is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group and its Standing Committee on Pandemics; he is also a member of the UK Government's New and Emerging Respiratory Virus Threats Risk Stratification Subgroup and a member of AstraZeneca's Thrombotic Thrombocytopenic Taskforce. All roles are unremunerated. VdAO, VB, MLB, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for the public health service use. All other authors declare no competing interests. Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE?The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). Additional support has been provided through Public Health Scotland and Scottish Government Director General Health and Social Care. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK government. The Brazilian component is part of the Fiocruz VigiVac project on continuous digital evaluation of the national anti-COVID-19 immunisation programme. SVK and SA acknowledge funding from an NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the MRC (MC_UU_00022/2), and the Scottish Government Chief Scientist Office (SPHSU17). This partnership between Brazil and Scotland was established through funding from the NIHR (GHRG /16/137/99) using UK aid from the UK Government to support global health research. This study was partially supported by a donation from the Fazer o Bem Faz Bem programme. The authors thank DATASUS for its excellent work in providing unidentified databases. GLW, MLB, and MB-N are research fellows from the Brazilian National Research Council. GLW acknowledges funding from FAPERJ (Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro; E-26/210.180/2020). We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available; Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK); and Pam McVeigh, Amanda Burridge, and Afshin Dastafshan (Public Health Scotland, Glasgow, UK) for their support with project management and administration. Publisher Copyright: © 2022 The author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseen
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.rightsUnder a Creative Commons license https://creativecommons.org/licenses/by/4.0/en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectSDG 9 - Industry, Innovation, and Infrastructureen
dc.subjectR Medicineen
dc.subjectMedicine(all)en
dc.subjectMedical Research Council (MRC)en
dc.subjectMC_PC_19075en
dc.subjectMC_PC_19004en
dc.subjectMC_PC_20058en
dc.subjectMC_UU_00022/2en
dc.subjectChief Scientist Office (CSO)en
dc.subjectSPHSU17en
dc.subject.lccRen
dc.titleTwo-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time : a retrospective, population-based cohort study in Scotland and Brazilen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(21)02754-9
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85121923761&partnerID=8YFLogxKen
dc.identifier.vol399en
dc.identifier.iss10319en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record